Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) CEO and Chief Scientific Officer Dr Kunwar Shailubhai tells Proactive the US and UK-based biotechnology company has developed an antibody that holds 'distinct advantages' over biotech giants Sanofi and Roche's drugs.
Dr Shailubhai says dual mechanism of action to inhibit signalling by the membrane-bound and soluble IL-6 receptors along with the rapid depletion of circulating IL-6 cytokine make its antibody unique. The company recently raised gross proceeds of approximately $10 million to help fund development efforts.